

## NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

## Single Technology Appraisal


# Tislelizumab with chemotherapy for untreated advanced oesophageal squamous cell cancer ID5113

### **Provisional Stakeholder List**

Consultees	Commentators (no right to submit or
	appeal)
<ul> <li><u>Company</u></li> <li>BeiGene (tislelizumab)</li> </ul>	<ul> <li><u>General</u></li> <li>All Wales Therapeutics and Toxicology Centre</li> </ul>
<ul> <li>Patient/carer groups</li> <li>Barrett's UK – previously Barrett's Oesophagus Campaign</li> <li>Black Health Agency for Equality</li> <li>Cancer Black Care</li> <li>Cancer 52</li> <li>GIST Cancer UK</li> <li>GUTS UK</li> <li>Heartburn Cancer UK</li> <li>Helen Rollason Cancer Charity</li> <li>Independent Cancer Patients Voice</li> <li>Macmillan Cancer Support</li> <li>Maggie's Centres</li> <li>Marie Curie</li> <li>Ochre</li> <li>Oesophageal Patients Association now known as OPA Cancer Charity Oesophageal and Gastric Support</li> <li>OG Support</li> <li>South Asian Health Foundation</li> </ul>	<ul> <li>Allied Health Professionals Federation</li> <li>Board of Community Health Councils in Wales</li> <li>British National Formulary</li> <li>Care Quality Commission</li> <li>Department of Health, Social Services and Public Safety for Northern Ireland</li> <li>Healthcare Improvement Scotland</li> <li>Medicines and Healthcare products Regulatory Agency</li> <li>National Association of Primary Care</li> <li>National Pharmacy Association</li> <li>NHS Confederation</li> <li>NHS Wales Joint Commissioning Committee</li> <li>Scottish Medicines Consortium</li> <li>Welsh Government</li> </ul>
<ul><li>Specialised Healthcare Alliance</li><li>Tenovus Cancer Care</li></ul>	<ul> <li>fluorouracil, oxaliplatin)</li> <li>Amarox (capecitabine, cisplatin)</li> <li>AS Kalceks (oxaliplatin)</li> </ul>
<ul> <li><u>Healthcare professional groups</u></li> <li>Association of Anaesthetists</li> <li>Association of Cancer Physicians</li> <li>Association of Surgeons of Great Britain and Ireland</li> <li>Association of Upper Gastrointestinal Surgeons of Great Britain and Ireland</li> <li>British Association of Surgical Oncology</li> <li>British Geriatrics Society</li> </ul>	<ul> <li>Bristol-Myers Squibb (nivolumab)</li> <li>Dr. Reddy's Laboratories (capecitabine)</li> <li>Glenmark Pharmaceuticals (capecitabine)</li> <li>Hospira UK (cisplatin, fluorouracil, oxaliplatin)</li> <li>Medac (epirubicin, fluorouracil, oxaliplatin)</li> <li>Morningside Healthcare (capecitabine)</li> <li>MSD (pembrolizumab)</li> </ul>

Provisional stakeholder list for the evaluation of tislelizumab with chemotherapy for untreated advanced oesophageal squamous cell cancer ID5113 Issue date: March 2025

© National Institute for Health and Care Excellence 2025. All rights reserved.



Consultees	Commentators (no right to submit or appeal)
<ul> <li>British Institute of Radiology</li> <li>British Oncology Pharmacy Association</li> <li>British Psychosocial Oncology Society</li> <li>British Society of Gastroenterology</li> <li>Cancer Research UK</li> <li>Primary Care Society for Gastroenterology</li> <li>Royal College of Anaesthetists</li> <li>Royal College of General Practitioners</li> <li>Royal College of Pathologists</li> <li>Royal College of Physicians</li> <li>Royal College of Surgeons</li> <li>Royal College of Surgeons</li> <li>Royal Society of Medicine</li> <li>Society and College of Radiologists</li> <li>UK Clinical Pharmacy Association</li> <li>UK Oncology Nursing Society</li> <li>Others</li> <li>Department of Health and Social Care</li> <li>NHS England</li> </ul>	<ul> <li>Pfizer (epirubicin)</li> <li>Ranbaxy (oxaliplatin)</li> <li>Sandoz (cisplatin)</li> <li>Seacross Pharmaceuticals (epirubicin, oxaliplatin)</li> <li><u>Relevant research groups</u></li> <li>Genomics England</li> <li>Institute of Cancer Research</li> <li>MRC Clinical Trials Unit</li> <li>National Institute for Health Research</li> <li><u>Associated Public Health groups</u></li> <li>Public Health Wales</li> <li>UK Health Security Agency</li> </ul>

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.


## **Definitions:**

Consultee or commentator stakeholders are provisional until a signed Confidentiality Agreement & Undertaking form is submitted to NICE at the evaluation stage. Participating stakeholders will be listed on the project information page for the evaluation.

#### **Consultees**

Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and relevant NHS organisations in England.

Provisional stakeholder list for the evaluation of tislelizumab with chemotherapy for untreated advanced oesophageal squamous cell cancer ID5113 Issue date: March 2025 © National Institute for Health and Care Excellence 2025. All rights reserved. 2 of 3



The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Draft Guidance (FDG).

All non-company consultees are invited to submit a statement relevant to the group they are representing, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Draft Guidance (FDG).

#### **Commentators**

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC]); other groups (for example, the NHS Confederation and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.